October is Breast Cancer Awareness Month, and this Saturday, WABC-TV will air a special feature, “Breast Cancer: Second Chances & New Advances” at 7:30PM. Hosted by Eyewitness News Anchor, Diana Williams, the breast cancer special highlights new advances that are helping those who are newly diagnosed or dealing with a recurrence.
While scientists work on the search for a cure, exciting progress has been made for those dealing with the worst form of breast cancer, triple negative breast cancer (TNBC). Dr. Linda Vahdat from the Weill Cornell Breast Center and NewYork-Presbyterian Hospital talks about the effects of copper depletion in the body. In addition to hearing about promising clinical trial results, hear from participating survivors who are living proof of the progress being made in the fight against TNBC, with hopes of FDA approval in the near future.
Additionally, doctors and researchers from other area medical centers share the latest on breast conservation for patients who have had a recurrence and new advances in immunotherapy offering targeted treatments for survivors.
This annual special is part of WABC-TV’s commitment to the American Cancer Society’s Making Strides Against Breast Cancer campaign. Learn more.
Dr. Linda Vahdat, director of the Weill Cornell Breast Center Research Program and Chief of the Solid Tumor Service at Weill Cornell, will be presenting a metastatic breast cancer research update for Living Beyond Breast Cancer’s free webinar on
Wednesday, October 16th from 12 noon to 1 pm.
In the webinar, Dr. Vahdat will help viewers explore:
- the latest clinical trial findings and their impact on today’s available treatment options
- novel therapies in the research pipeline and the role they may play in future care
- the latest understanding of what may cause metastasis and how we might prevent it in the future
Click here for more information about the free webinar. Click here to register for the webinar.
“Taking Tamoxifen 5 years vs. 10 Years”
The Weill Cornell Breast Center is hosting a seminar on the latest news from the San Antonio Breast Cancer Conference regarding treatment after breast cancer.
WHEN: Thursday, January 17, 2013
WHERE: 1305 York Avenue (at 70th Street) 2nd Floor, Conference Room B
Refreshments will be served.
N093B: Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer
The Weill Cornell Breast Center has recently opened a new clinical trial for people with metastatic breast cancer that is considered “triple negative,” meaning breast cancer that does not express genes for estrogen receptor (ER), progesterone receptor (PR) or HER2. The study sponsor is the Cancer Trials Support Unit (CTSU)/North Central Cancer Treatment Group. The principal investigator at Weill Cornell is Dr. Tessa Cigler. For more information about the study, please call Marta Cobham, RN at (212) 821-0780 or e-mail Marta at firstname.lastname@example.org.
The purpose of this study is to determine how well people with metastatic breast cancer respond to treatment with the experimental drug panobinostat (also called LBH589) when it is given with letrozole. The study will also evaluate the safety of panobinostat when combined with letrozole.
Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat together with letrozole may be an effective treatment for breast cancer.
Treatment cycles in this study are 28 days. Study participants will take panobinostat (as a tablet by mouth) once daily on Days 1, 3 and 5 in weeks 1-4 and oral letrozole once daily on days 1-28. Treatment cycles repeat every 28 days as long as participants are responding to treatment and tolerating the medications. After completing study therapy, participants will be followed up every 3 to 6 months for up to 5 years.
- Men and women with metastatic breast cancer
- Cancer must be unresected (has not been removed by surgery)
- Women must be postmenopausal based on one of the following criteria:
- Age 60 or older
- Age 45 or older with last menstrual period ≥12 months before entering the study
- Bilateral oophorectomy (surgical removal of both ovaries)
- Men must be age 18 or older
- Prior therapy:
- Zero or 1 prior chemotherapy regimens for breast cancer (no more than 1 prior chemotherapy regimen)
- ≤2 prior aromatase inhibitor regimens (including letrozole)
- Detailed eligibility reviewed when you contact the study team